18 research outputs found
Estrategias de mejora en el diagnóstico del cáncer de mama por imagen de resonancia magnética: Avances en la secuencia potenciada en difusión
Desde la introducción de la imagen eco-planar para la obtención de la imagen potenciada en difusión (IPD), esta secuencia se utiliza cada vez más en la práctica clínica para la detección y caracterización de las lesiones mamarias. La IPD eco-planar de disparo único carece de una alta resolución espacial y es sensible al movimiento y a la falta de homogeneidad del campo magnético lo que puede generar artefactos en la imagen que a menudo dificultan una adecuada delimitación de las lesiones, en especial aquellas de menor tamaño. Las secuencias de difusión eco-planares de disparo múltiple ofrecen una mayor resolución espacial, pero son susceptibles a errores de fase inducidos por el movimiento, ya que cada disparo individual puede tener una dirección de codificación diferente. Esto produce artefactos tipo fantasma, registro erróneo de pixeles y una baja resolución de imagen con pobre contraste de difusión en las imágenes generadas. Además, los valores del coeficiente de difusión aparente (CDA) pueden verse alterados arrojando medidas inexactas que pueden afectar al diagnóstico. Una de las técnicas más prometedoras para corregir los errores de fase inducidos por el movimiento es la imagen potenciada en difusión decodificación de sensibilidad multiplexada (IPDCSM). Esta técnica utiliza el método de imagen paralela llamado de codificación de sensibilidad (SENSE por sus siglas en inglés) multiplexado logrando una mejor relación señal ruido(RSR). La IPDCSM reduce los artefactos y las distorsiones geométricas sin necesidad de ecos de navegación o modificaciones en la secuencia de pulsos. Esto genera imágenes de alta resolución con tiempos de adquisición cortos que permiten su aplicabilidad clínica. Este trabajo constituye la primera experiencia de esta secuencia aplicada a la imagen mamaria..
Radiomics and Machine Learning with Multiparametric Breast MRI for Improved Diagnostic Accuracy in Breast Cancer Diagnosis.
Recommended from our members
Combining molecular and imaging metrics in cancer: radiogenomics.
BACKGROUND: Radiogenomics is the extension of radiomics through the combination of genetic and radiomic data. Because genetic testing remains expensive, invasive, and time-consuming, and thus unavailable for all patients, radiogenomics may play an important role in providing accurate imaging surrogates which are correlated with genetic expression, thereby serving as a substitute for genetic testing. MAIN BODY: In this article, we define the meaning of radiogenomics and the difference between radiomics and radiogenomics. We provide an up-to-date review of the radiomics and radiogenomics literature in oncology, focusing on breast, brain, gynecological, liver, kidney, prostate and lung malignancies. We also discuss the current challenges to radiogenomics analysis. CONCLUSION: Radiomics and radiogenomics are promising to increase precision in diagnosis, assessment of prognosis, and prediction of treatment response, providing valuable information for patient care throughout the course of the disease, given that this information is easily obtainable with imaging. Larger prospective studies and standardization will be needed to define relevant imaging biomarkers before they can be implemented into the clinical workflow
Recommended from our members
High-Spatial-Resolution Multishot Multiplexed Sensitivity-encoding Diffusion-weighted Imaging for Improved Quality of Breast Images and Differentiation of Breast Lesions: A Feasibility Study.
Multishot multiplexed sensitivity-encoding diffusion-weighted imaging is a feasible and easily implementable routine breast MRI protocol that yields high-quality diffusion-weighted breast images.Purpose: To compare multiplexed sensitivity-encoding (MUSE) diffusion-weighted imaging (DWI) and single-shot DWI for lesion visibility and differentiation of malignant and benign lesions within the breast.Materials and Methods: In this prospective institutional review board-approved study, both MUSE DWI and single-shot DWI sequences were first optimized in breast phantoms and then performed in a group of patients. Thirty women (mean age, 51.1 years ± 10.1 [standard deviation]; age range, 27-70 years) with 37 lesions were included in this study and underwent scanning using both techniques. Visual qualitative analysis of diffusion-weighted images was accomplished by two independent readers; images were assessed for lesion visibility, adequate fat suppression, and the presence of artifacts. Quantitative analysis was performed by calculating apparent diffusion coefficient (ADC) values and image quality parameters (signal-to-noise ratio [SNR] for lesions and fibroglandular tissue; contrast-to-noise ratio) by manually drawing regions of interest within the phantoms and breast tumor tissue. Interreader variability was determined using the Cohen κ coefficient, and quantitative differences between MUSE DWI and single-shot DWI were assessed using the Mann-Whitney U test; significance was defined at P < .05.Results: MUSE DWI yielded significantly improved image quality compared with single-shot DWI in phantoms (SNR, P = .001) and participants (lesion SNR, P = .009; fibroglandular tissue SNR, P = .05; contrast-to-noise ratio, P = .008). MUSE DWI ADC values showed a significant difference between malignant and benign lesions (P < .001). No significant differences were found between MUSE DWI and single-shot DWI in the mean, maximum, and minimum ADC values (P = .96, P = .28, and P = .49, respectively). Visual qualitative analysis resulted in better lesion visibility for MUSE DWI over single-shot DWI (κ = 0.70).Conclusion: MUSE DWI is a promising high-spatial-resolution technique that may enhance breast MRI protocols without the need for contrast material administration in breast screening.Keywords: Breast, MR-Diffusion Weighted Imaging, OncologySupplemental material is available for this article.© RSNA, 2020
Automated breast ultrasound for the detection of breast lesions: Comparison with hand-held ultrasound
Objetivos: Comparar la ecografía convencional frente a la ecografía automática de mama
(ABUS) y la mamografía con tomosíntesis aislada en la detección y el diagnóstico de lesiones
mamarias.
Sujetos y métodos: Se incluyeron 155 mujeres sintomáticas y asintomáticas con mamas densas.
Todas se realizaron mamografía y seguidamente ecografía manual y ABUS, que fueron interpretadas por 2 radiólogos diferentes. Los estudios fueron categorizados según el Breast Imaging
Reporting and Data System (BI-RADS).
Resultados: El índice kappa de concordancia fue de 0,83, p < 0,05. Los 5 carcinomas encontrados
fueron diagnosticados por ambas técnicas de imagen de ultrasonidos, siendo en 2 de ellos la
mamografía normal. ABUS detectó 2 lesiones benignas no vistas con la ecografía manual.
Conclusión: ABUS demostró alta correlación con la ecografía manual detectando más lesiones benignas. El diagnóstico de las malignas fue equivalente con ambas técnicas, que fueron
superiores a la mamografía de forma aislada. ABUS podría sustituir a la ecografía manual para
complementar a la mamografía en la detección de cáncer de mama en mujeres con mama
densa.Objectives: To compare automated breast ultrasound (ABUS) with hand-held ultrasound (HHUS)
and tomosynthesis mammography in the detection and characterisation of breast lesions.
Subjects and methods: A total of 155 symptomatic and asymptomatic women with dense
breasts underwent tomosynthesis followed by ABUS and HHUS. The studies were read and graded by two different radiologists according to the Breast Imaging Reporting and Data System
(BI-RADS).
Results: The kappa index of agreement was 0.83, p < 0.05. All of the 5 carcinomas found were
diagnosed by ABUS and HHUS. Tomosynthesis was normal in 2 out of 5 cases. ABUS identified
2 benign lesions not detected with HHUS.
Conclusion: This study found a high correlation between ABUS and HHUS. More benign lesions
were identified by ABUS while malignant lesions were detected equally by both techniques.
ABUS and HHUS were superior to tomosynthesis in the detection of lesions. ABUS could replace
HHUS, complementing mammography in the detection of lesions in women with dense breasts.Sin financiaciónNo data JCR 20180.120 SJR (2018) Q4, 319/381 Oncology, 287/341 Radiology, Nuclear Medicine and ImagingNo data IDR 2018UE
Recommended from our members
MRI background parenchymal enhancement, fibroglandular tissue, and mammographic breast density in patients with invasive lobular breast cancer on adjuvant endocrine hormonal treatment: associations with survival.
BACKGROUND: To investigate if baseline and/or changes in contralateral background parenchymal enhancement (BPE) and fibroglandular tissue (FGT) measured on magnetic resonance imaging (MRI) and mammographic breast density (MD) can be used as imaging biomarkers for overall and recurrence-free survival in patients with invasive lobular carcinomas (ILCs) undergoing adjuvant endocrine treatment. METHODS: Women who fulfilled the following inclusion criteria were included in this retrospective HIPAA-compliant IRB-approved study: unilateral ILC, pre-treatment breast MRI and/or mammography from 2000 to 2010, adjuvant endocrine treatment, follow-up MRI, and/or mammography 1-2 years after treatment onset. BPE, FGT, and mammographic MD of the contralateral breast were independently graded by four dedicated breast radiologists according to BI-RADS. Associations between the baseline levels and change in levels of BPE, FGT, and MD with overall survival and recurrence-free survival were assessed using Kaplan-Meier survival curves and Cox regression analysis. RESULTS: Two hundred ninety-eight patients (average age = 54.1 years, range = 31-79) fulfilled the inclusion criteria. The average follow-up duration was 11.8 years (range = 2-19). Baseline and change in levels of BPE, FGT, and MD were not significantly associated with recurrence-free or overall survival. Recurrence-free and overall survival were affected by histological subtype (p < 0.0001), number of metastatic axillary lymph nodes (p < 0.0001), age (p = 0.01), and adjuvant endocrine treatment duration (p < 0.001). CONCLUSIONS: Qualitative evaluation of BPE, FGT, and mammographic MD changes cannot predict which patients are more likely to benefit from adjuvant endocrine treatment
Recommended from our members
Diagnostic value of diffusion-weighted imaging with synthetic b-values in breast tumors: comparison with dynamic contrast-enhanced and multiparametric MRI.
OBJECTIVES: To assess DWI for tumor visibility and breast cancer detection by the addition of different synthetic b-values. METHODS: Eighty-four consecutive women who underwent a breast-multiparametric-MRI (mpMRI) with enhancing lesions on DCE-MRI (BI-RADS 2-5) were included in this IRB-approved retrospective study from September 2018 to March 2019. Three readers evaluated DW acquired b-800 and synthetic b-1000, b-1200, b-1500, and b-1800 s/mm2 images for lesion visibility and preferred b-value based on lesion conspicuity. Image quality (1-3 scores) and breast composition (BI-RADS) were also recorded. Diagnostic parameters for DWI were determined using a 1-5 malignancy score based on qualitative imaging parameters (acquired + preferred synthetic b-values) and ADC values. BI-RADS classification was used for DCE-MRI and quantitative ADC values + BI-RADS were used for mpMRI. RESULTS: Sixty-four malignant (average = 23 mm) and 39 benign (average = 8 mm) lesions were found in 80 women. Although b-800 achieved the best image quality score, synthetic b-values 1200-1500 s/mm2 were preferred for lesion conspicuity, especially in dense breast. b-800 and synthetic b-1000/b-1200 s/mm2 values allowed the visualization of 84-90% of cancers visible with DCE-MRI performing better than b-1500/b-1800 s/mm2. DWI was more specific (86.3% vs 65.7%, p < 0.001) but less sensitive (62.8% vs 90%, p < 0.001) and accurate (71% vs 80.7%, p = 0.003) than DCE-MRI for breast cancer detection, where mpMRI was the most accurate modality accounting for less false positive cases. CONCLUSION: The addition of synthetic b-values enhances tumor conspicuity and could potentially improve tumor visualization particularly in dense breast. However, its supportive role for DWI breast cancer detection is still not definite. KEY POINTS: • The addition of synthetic b-values (1200-1500 s/mm2) to acquired DWI afforded a better lesion conspicuity without increasing acquisition time and was particularly useful in dense breasts. • Despite the use of synthetic b-values, DWI was less sensitive and accurate than DCE-MRI for breast cancer detection. • A multiparametric MRI modality still remains the best approach having the highest accuracy for breast cancer detection and thus reducing the number of unnecessary biopsies
Recommended from our members
Improved characterization of sub-centimeter enhancing breast masses on MRI with radiomics and machine learning in BRCA mutation carriers.
OBJECTIVES: To investigate whether radiomics features extracted from MRI of BRCA-positive patients with sub-centimeter breast masses can be coupled with machine learning to differentiate benign from malignant lesions using model-free parameter maps. METHODS: In this retrospective study, BRCA-positive patients who had an MRI from November 2013 to February 2019 that led to a biopsy (BI-RADS 4) or imaging follow-up (BI-RADS 3) for sub-centimeter lesions were included. Two radiologists assessed all lesions independently and in consensus according to BI-RADS. Radiomics features were calculated using open-source CERR software. Univariate analysis and multivariate modeling were performed to identify significant radiomics features and clinical factors to be included in a machine learning model to differentiate malignant from benign lesions. RESULTS: Ninety-six BRCA mutation carriers (mean age at biopsy = 45.5 ± 13.5 years) were included. Consensus BI-RADS classification assessment achieved a diagnostic accuracy of 53.4%, sensitivity of 75% (30/40), specificity of 42.1% (32/76), PPV of 40.5% (30/74), and NPV of 76.2% (32/42). The machine learning model combining five parameters (age, lesion location, GLCM-based correlation from the pre-contrast phase, first-order coefficient of variation from the 1st post-contrast phase, and SZM-based gray level variance from the 1st post-contrast phase) achieved a diagnostic accuracy of 81.5%, sensitivity of 63.2% (24/38), specificity of 91.4% (64/70), PPV of 80.0% (24/30), and NPV of 82.1% (64/78). CONCLUSIONS: Radiomics analysis coupled with machine learning improves the diagnostic accuracy of MRI in characterizing sub-centimeter breast masses as benign or malignant compared with qualitative morphological assessment with BI-RADS classification alone in BRCA mutation carriers. KEY POINTS: • Radiomics and machine learning can help differentiate benign from malignant breast masses even if the masses are small and morphological features are benign. • Radiomics and machine learning analysis showed improved diagnostic accuracy, specificity, PPV, and NPV compared with qualitative morphological assessment alone
Recommended from our members
MRI-based machine learning radiomics can predict HER2 expression level and pathologic response after neoadjuvant therapy in HER2 overexpressing breast cancer.
BACKGROUND: To use clinical and MRI radiomic features coupled with machine learning to assess HER2 expression level and predict pathologic response (pCR) in HER2 overexpressing breast cancer patients receiving neoadjuvant chemotherapy (NAC). METHODS: This retrospective study included 311 patients. pCR was defined as no residual invasive carcinoma in the breast or axillary lymph nodes (ypT0/isN0). Radiomics/statistical analysis was performed using MATLAB and CERR software. After ROC and correlation analysis, selected radiomics parameters were advanced to machine learning modelling alongside clinical MRI-based parameters (lesion type, multifocality, size, nodal status). For predicting pCR, the data was split into a training and test set (80:20). FINDINGS: The overall pCR rate was 60.5% (188/311). The final model to predict HER2 heterogeneity utilised three MRI parameters (two clinical, one radiomic) for a sensitivity of 99.3% (277/279), specificity of 81.3% (26/32), and diagnostic accuracy of 97.4% (303/311). The final model to predict pCR included six MRI parameters (two clinical, four radiomic) for a sensitivity of 86.5% (32/37), specificity of 80.0% (20/25), and diagnostic accuracy of 83.9% (52/62) (test set); these results were independent of age and ER status, and outperformed the best model developed using clinical parameters only (p=0.029, comparison of proportion Chi-squared test). INTERPRETATION: The machine learning models, including both clinical and radiomics MRI features, can be used to assess HER2 expression level and can predict pCR after NAC in HER2 overexpressing breast cancer patients. FUNDING: NIH/NCI (P30CA008748), Susan G. Komen Foundation, Breast Cancer Research Foundation, Spanish Foundation Alfonso Martin Escudero, European School of Radiology
Diagnostic value of radiomics and machine learning with dynamic contrast-enhanced magnetic resonance imaging for patients with atypical ductal hyperplasia in predicting malignant upgrade.
PURPOSE: To investigate whether radiomics features extracted from magnetic resonance imaging (MRI) of patients with biopsy-proven atypical ductal hyperplasia (ADH) coupled with machine learning can differentiate high-risk lesions that will upgrade to malignancy at surgery from those that will not, and to determine if qualitatively and semi-quantitatively assessed imaging features, clinical factors, and image-guided biopsy technical factors are associated with upgrade rate. METHODS: This retrospective study included 127 patients with 139 breast lesions yielding ADH at biopsy who were assessed with multiparametric MRI prior to biopsy. Two radiologists assessed all lesions independently and with a third reader in consensus according to the BI-RADS lexicon. Univariate analysis and multivariate modeling were performed to identify significant radiomic features to be included in a machine learning model to discriminate between lesions that upgraded to malignancy on surgery from those that did not. RESULTS: Of 139 lesions, 28 were upgraded to malignancy at surgery, while 111 were not upgraded. Diagnostic accuracy was 53.6%, specificity 79.2%, and sensitivity 15.3% for the model developed from pre-contrast features, and 60.7%, 86%, and 22.8% for the model developed from delta radiomics datasets. No significant associations were found between any radiologist-assessed lesion parameters and upgrade status. There was a significant correlation between the number of specimens sampled during biopsy and upgrade status (p = 0.003). CONCLUSION: Radiomics analysis coupled with machine learning did not predict upgrade status of ADH. The only significant result from this analysis is between the number of specimens sampled during biopsy procedure and upgrade status at surgery